Recently, molecular diagnostic developer Cepheid announced that the FDA has approved a new generation of rapid detection equipment for methicillin-staphylococcus aureus (MRSA) infection Xpert MRSA
The NxG is listed to combat the growing MRSA transmission in recent years.
The device is based on the company's unique molecular detection method platform GeneXpert, a new detection device that quickly detects whether a patient has received an MRSA infection within an hour. Xpert
MRSA
NxG developers have developed this product based on a library of MRSA strains from around the world, which covers a library of information larger than previous assays and incorporates the latest PCR primers and probe technology. So Xpert
MRSA NxG minimizes false positive results that may occur during testing.
In recent years, antibiotics have emerged because of the abuse of antibiotics. MRSA is the most common class of drug-resistant bacteria in the clinic. Dr. Fred, vice chairman of the company responsible for scientific affairs
Tenover said that the Xpert MRSA NxG can help clinicians control MRSA infections in a timely manner and kill them before a possible outbreak begins.
In fact, the company's new technology has also received widespread attention in the industry. In September, Danaher signed an agreement with Cepheid to announce its acquisition for $4 billion.
The history of human medical development is almost a battle history with viruses and bacteria. Almost all major epidemics in history have been related to this. After the advent of penicillin in the last century, antibiotics have developed rapidly. Some even believe that human beings have achieved a final victory. However, contrary to expectations, with the development of antibiotics, more and more antibiotics have entered the human eye. In the end, even the development efficiency of new antibiotics lags far behind the emergence of antibiotics. As a result, more and more biopharmaceutical companies have gradually withdrawn from the field of antibiotic research and development. In fact, the shortage of antibiotics has also attracted the attention of relevant departments in the world, and they have formulated their own preferential policies. These policies have already begun to bear fruit in recent years, and some biopharmaceutical companies that have long since left antibiotic research have returned to this field. Prior to this, both Merck and Roche have re-started research on new antibiotic drug projects.
Disposable Suture Dressing Bag
Medical Wound Care Bag,Disposable Suture Package,Disposable Suture Dressing Bag,Disposable Sterile Dressing Bag
Henan Zhongjian Medical Equipment Co., Ltd. , https://www.hnzjmedical.com